Table 2.
Risk points, each corresponding to a five-fold increased risk, are added, yielding a risk score.
| 1 point | 2 points | 3 points | >4 points5 | Very high risk6 |
|---|---|---|---|---|
| Heterozygote FV Leiden | Prot S deficiency | Homo FV Leiden | Prior VTE | Mechanical heart prosthesis |
| Heterozygote FII mut | Prot C deficiency | Homo FII mut | APS without VTE7 | Chronic warfarin prophylaxis |
| Overweight1 | Immobilization4 | Antithrombin deficiency | ||
| Cesarean Section | Recurrent VTE | |||
| Heredity for VTE2 | APS with VTE7 | |||
| Age >40 years | ||||
| Preeclampsia | ||||
| Hyperhomocysteinemia3 | ||||
| Abruptio placenta | ||||
| Inflammatory bowel disease | ||||
| Other major riskfactor |
Homo: Homozygote, mut: mutation, VTE: venous thrombembolism.
APS: Antiphospholipidsyndrome, Prot: protein, FV: faktor V, FII: factor II (prothrombin).
1Overweight = (BMI >28 in early pregnancy).
2VTE in first-degree relative <60 years of age.
3Homocysteine >8 μmol/L in pregnancy.
4During cast treatment for fracture or strict bed rest short-term thromboprophylaxis is recommended.
5Women with prior VTE or APS without VTE have risk score 4 independent of other risk factors.
6Women in this group are classified as “very high risk” and are not scored.
7Women with APS are recommended low dose (75 mg) acetylsalicylic acid in addition to LMWH.
The risk score is formed by adding each point to a score between 0 and maximum 4 (for >4 points).